Nintedanib

MedicationExperimental0 reviews

—

Average score out of 5

Experimental — This treatment is under research. Available data is limited. Consult your doctor before making any decision.

Nintedanib is an antifibrotic tyrosine kinase inhibitor approved for idiopathic pulmonary fibrosis. It is being studied off-label in Long COVID for persistent pulmonary fibrosis and post-COVID lung damage.

Information

Subcategory: antifibrotic tyrosine kinase inhibitor
Evidence level: 2/5
Evidence type: preliminary clinical trials on post-COVID pulmonary sequelae

Share your experience

Your feedback helps thousands of people find what really works.

Join the community